Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis
Open Access
- 15 November 2017
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 19 (1) , 1-8
Abstract
Rheumatoid arthritis patients are at higher risk of developing comorbidities. The main objective of this study was to evaluate the prevalence of major comorbidities in Chinese rheumatoid arthritis patients. We also aimed to identify factors associated with these comorbidities. Baseline demographic, clinical characteristics and comorbidity data from RA patients enrolled in the Chinese Registry of rhEumatoiD arthrITis (CREDIT) from Nov 2016 to August 2017 were presented and compared with those from five other registries across the world. Possible factors related to three major comorbidities (cardiovascular disease, fragility fracture and malignancy) were identified using multivariate logistic regression analyses. A total of 13,210 RA patients were included (80.6% female, mean age 52.9 years and median RA duration 4.0 years). Baseline prevalence rates of major comorbidities were calculated: CVD, 2.2% (95% CI 2.0–2.5%); fragility fracture, 1.7% (95% CI 1.5–1.9%); malignancy, 0.6% (95% CI 0.5–0.7%); overall major comorbidities, 4.2% (95% CI 3.9–4.6%). Advanced age was associated with all comorbidities. Male gender and disease duration were positively related to CVD. Female sex and longer disease duration were potential risk factors for fragility fractures. Ever use of methotrexate (MTX) was negatively related to baseline comorbidities. Patients with rheumatoid arthritis in China have similar prevalence of comorbidities with other Asian countries. Advanced age and long disease duration are possible risk factors for comorbidities. On the contrary, MTX may protect RA patients from several major comorbidities, supporting its central role in the management of rheumatoid arthritis.Keywords
Funding Information
- Chinese National Key Research R&D Program (2017YFC0907601, 2017YFC0907604)
This publication has 44 references indexed in Scilit:
- Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?Arthritis & Rheumatology, 2017
- Cardiovascular disease in rheumatoid arthritis: medications and risk factors in ChinaClinical Rheumatology, 2017
- Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory StatesArthritis Care & Research, 2016
- Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular diseaseAnnals of the Rheumatic Diseases, 2016
- Cardiovascular comorbidity in rheumatic diseasesNature Reviews Rheumatology, 2015
- Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysisArthritis Research & Therapy, 2015
- Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational RegistriesArthritis Care & Research, 2015
- Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fractureOsteoporosis International, 2014
- Chronic Inflammatory Diseases and Cardiovascular Risk: A Systematic ReviewCanadian Journal of Cardiology, 2011
- Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexateArthritis Care & Research, 2008